GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA) » Definitions » Beneish M-Score

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Beneish M-Score

: -4.42 (As of Today)
View and export this data going back to 2021. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.42 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ginkgo Bioworks Holdings's Beneish M-Score or its related term are showing as below:

DNA' s Beneish M-Score Range Over the Past 10 Years
Min: -6.39   Med: -5.41   Max: -4.42
Current: -4.42

During the past 5 years, the highest Beneish M-Score of Ginkgo Bioworks Holdings was -4.42. The lowest was -6.39. And the median was -5.41.


Ginkgo Bioworks Holdings Beneish M-Score Historical Data

The historical data trend for Ginkgo Bioworks Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - -6.39 -4.42

Ginkgo Bioworks Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.39 -5.85 -5.35 -4.30 -4.42

Competitive Comparison

For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ginkgo Bioworks Holdings Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ginkgo Bioworks Holdings's Beneish M-Score falls into.



Ginkgo Bioworks Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ginkgo Bioworks Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7176+0.528 * 0.7291+0.404 * 1.0964+0.892 * 0.5264+0.115 * 0.3813
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5116+4.679 * -0.249499-0.327 * 1.0032
=-4.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $31.7 Mil.
Revenue was 34.755 + 55.43 + 80.568 + 80.702 = $251.5 Mil.
Gross Profit was 28.144 + 48.507 + 62.472 + 58.327 = $197.5 Mil.
Total Current Assets was $1,001.7 Mil.
Total Assets was $1,665.3 Mil.
Property, Plant and Equipment(Net PPE) was $397.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $71.6 Mil.
Selling, General, & Admin. Expense(SGA) was $385.0 Mil.
Total Current Liabilities was $163.9 Mil.
Long-Term Debt & Capital Lease Obligation was $221.8 Mil.
Net Income was -211.694 + -302.891 + -173.315 + -204.969 = $-892.9 Mil.
Non Operating Income was -46.985 + -127.75 + -3.446 + -3.687 = $-181.9 Mil.
Cash Flow from Operations was -57.831 + -73.551 + -73.533 + -90.585 = $-295.5 Mil.
Total Receivables was $84.0 Mil.
Revenue was 98.285 + 66.398 + 144.618 + 168.405 = $477.7 Mil.
Gross Profit was 68.067 + 41.743 + 80.707 + 82.973 = $273.5 Mil.
Total Current Assets was $1,450.1 Mil.
Total Assets was $2,539.3 Mil.
Property, Plant and Equipment(Net PPE) was $718.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $44.4 Mil.
Selling, General, & Admin. Expense(SGA) was $1,429.8 Mil.
Total Current Liabilities was $173.0 Mil.
Long-Term Debt & Capital Lease Obligation was $413.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(31.738 / 251.455) / (84.026 / 477.706)
=0.126217 / 0.175895
=0.7176

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(273.49 / 477.706) / (197.45 / 251.455)
=0.572507 / 0.78523
=0.7291

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1001.749 + 397.224) / 1665.342) / (1 - (1450.079 + 718.791) / 2539.321)
=0.159949 / 0.145886
=1.0964

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=251.455 / 477.706
=0.5264

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(44.423 / (44.423 + 718.791)) / (71.554 / (71.554 + 397.224))
=0.058205 / 0.152639
=0.3813

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(385.025 / 251.455) / (1429.799 / 477.706)
=1.531188 / 2.993052
=0.5116

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((221.835 + 163.86) / 1665.342) / ((413.256 + 172.962) / 2539.321)
=0.231601 / 0.230856
=1.0032

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-892.869 - -181.868 - -295.5) / 1665.342
=-0.249499

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ginkgo Bioworks Holdings has a M-score of -4.42 suggests that the company is unlikely to be a manipulator.


Ginkgo Bioworks Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Traded in Other Exchanges
Address
27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.
Executives
Jason R Kelly director, officer: CEO & Founder 667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065
Mark E. Dmytruk officer: Chief Financial Officer C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Barry Canton 10 percent owner C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Reshma P. Shetty director, 10 percent owner, officer: President, COO & Founder C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Harry Sloan director, officer: CEO, Chairman 1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401
Shyam Sankar director C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202
Steven P. Coen officer: Chief Accounting Officer C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marie E. Fallon officer: Chief Accounting Officer C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marijn E Dekkers director GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Kathy Hopinkah Hannan director ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830